EXOC1 Antibody (N-term) Blocking Peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | Q9NV70 |
---|
Gene ID | 55763 |
---|---|
Other Names | Exocyst complex component 1, Exocyst complex component Sec3, EXOC1, SEC3, SEC3L1 |
Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
Name | EXOC1 |
---|---|
Synonyms | SEC3, SEC3L1 |
Function | Component of the exocyst complex involved in the docking of exocytic vesicles with fusion sites on the plasma membrane. |
Cellular Location | Midbody, Midbody ring. Cytoplasm. Cytoplasm, perinuclear region. Cell membrane. Note=Colocalizes with CNTRL/centriolin at the midbody ring (PubMed:16213214). Localizes in cell membrane in the presence of SLC6A9 (PubMed:16181645). |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
EXOC1 is a component of the exocyst complex, a multiple protein complex essential for targeting exocytic vesicles to specific docking sites on the plasma membrane. Though best characterized in yeast, the component proteins and functions of the exocyst complex have been demonstrated to be highly conserved in higher eukaryotes. At least eight components of the exocyst complex, including this protein, are found to interact with the actin cytoskeletal remodeling and vesicle transport machinery. Alternatively spliced transcript variants encoding distinct isoforms have been described.
References
??ndersen, N.J., et al. Mol. Biol. Cell 21(1):152-164(2010)??akurai-Yageta, M., et al. J. Cell Biol. 181(6):985-998(2008)??su, S.C., et al. Int. Rev. Cytol. 233, 243-265 (2004) :??oskalenko, S., et al. J. Biol. Chem. 278(51):51743-51748(2003)??noue, M., et al. Nature 422(6932):629-633(2003)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.